Browsing Clinical Studies by author "van der Graaf, Wilhelmina"
Now showing items 1-20 of 44
-
A Specific Distress Cutoff Score Shortly After Breast Cancer Diagnosis.
Ploos van Amstel, FK; Tol, J; Sessink, KH; van der Graaf, WTA; Prins, JB; et al. (2017-05)Background High levels of distress are expected shortly after the diagnosis breast cancer. The Distress Thermometer (DT) is commonly used to screen for distress, using a cutoff score of 4 or 5; however, this score might ... -
Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor.
Desar, IME; Braam, PM; Kaal, SEJ; Gerritsen, WR; Oyen, WJG; et al. (2016-12) -
Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
Grünwald, V; Litière, S; Young, R; Messiou, C; Lia, M; et al. (2016-09)Background Anthracycline-based chemotherapy remains the mainstay of first-line treatment in metastatic or advanced soft-tissue sarcoma (STS). Age, performance status, tumour histology and tumour grade are recognised ... -
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
Schöffski, P; Wozniak, A; Stacchiotti, S; Rutkowski, P; Blay, J-Y; et al. (2017-12)Background Clear-cell sarcoma (CCSA) is an orphan malignancy, characterized by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the ... -
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.
Bol, KF; van den Bosch, T; Schreibelt, G; Mensink, HW; Keunen, JEE; et al. (2016-10) -
Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.
Boudewijns, S; Bol, KF; Schreibelt, G; Westdorp, H; Textor, JC; et al. (2016-07)Purpose To determine the effectiveness of adjuvant dendritic cell (DC) vaccination to induce tumor-specific immunological responses in stage III melanoma patients.Experimental design Retrospective analysis of stage III ... -
Age as an independent prognostic factor for survival of localised synovial sarcoma patients.
Vlenterie, M; Ho, VKY; Kaal, SEJ; Vlenterie, R; Haas, R; et al. (2015-12)Background We performed a retrospective nationwide study to explore age as a prognostic factor in synovial sarcoma patients.Methods Data on 613 synovial sarcoma patients were obtained from the Netherlands Cancer Registry. ... -
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).
Kasper, B; Baumgarten, C; Garcia, J; Bonvalot, S; Haas, R; et al. (2017-10)Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based ... -
Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
Boon, E; van Boxtel, W; Buter, J; Baatenburg de Jong, RJ; van Es, RJJ; et al. (2018-03)Background Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor-positive. Only limited data are available on androgen deprivation therapy (ADT).Methods Patients with advanced ... -
Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study.
Verboom, MC; Ouwerkerk, J; Steeghs, N; Lutjeboer, J; Martijn Kerst, J; et al. (2017-01-31)Background Trabectedin has shown efficacy against soft tissue sarcomas (STS) and has manageable toxicity. Trabectedin is administered through central venous access devices (VAD), such as subcutaneous ports with tunneled ... -
Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma.
Chew, W; Benson, C; Thway, K; Hayes, A; Miah, A; et al. (2018-09-05)<h4>Background</h4>Sclerosing epithelioid fibrosarcoma (SEF) is a very rare soft tissue sarcoma subtype. Clinically it is an aggressive tumour; however, to our knowledge there are no published reports regarding the efficacy ... -
Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
Farag, S; Somaiah, N; Choi, H; Heeres, B; Wang, W-L; et al. (2017-05)Purpose Patients, platelet-derived growth factor receptor alpha (PDGFRA) D842V-mutated gastrointestinal stromal tumours (GISTs) are known for their insensitivity to imatinib. However, in clinical practice responses have ... -
Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.
Boon, E; Valstar, MH; van der Graaf, WTA; Bloemena, E; Willems, SM; et al. (2018-07)OBJECTIVES:In 2010, a new subtype of salivary gland cancer (SGC), (mammary analogue) secretory carcinoma (SC), was defined, characterized by the ETV6-NTRK3 fusion gene. As clinical behavior and outcome data of this ... -
Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?
Lubberman, FJE; Gelderblom, H; Wilmer, CM; Kweekel, DM; Desar, IME; et al. (2017-10) -
Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.
Farag, S; van Coevorden, F; Sneekes, E; Grunhagen, DJ; Reyners, AKL; et al. (2017-11)Objective Although gastrointestinal stromal tumours (GIST) predominantly occur in older patients, data on treatment patterns in elderly GIST patients are scarce.Methods Patients registered in the Dutch GIST Registry (DGR) ... -
Fatigue in Advanced Cancer Patients: Congruence Between Patients and Their Informal Caregivers About Patients' Fatigue Severity During Cancer Treatment With Palliative Intent and Predictors of Agreement.
Poort, H; Peters, MEWJ; Gielissen, MFM; Verhagen, CAHHVM; Bleijenberg, G; et al. (2016-09)Context Informal caregivers (ICs) are increasingly involved in the monitoring of symptoms during advanced cancer patients' treatment with palliative intent. A common but subjective symptom during this extended treatment ... -
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.
Ray-Coquard, I; Rizzo, E; Blay, JY; Casali, P; Judson, I; et al. (2016-07)Objective UtS are a group of uncommon tumors representing 1% of malignant neoplasms of the female genital tract, and 7% of sarcomas. The objective of this study was to evaluate the factors associated with the clinical ...